| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



Sarcoma
Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study
Joonha Kwon, Jun Hyeong Lee, Young Han Lee, Jeeyun Lee, Jin-Hee Ahn, Se Hyun Kim, Seung Hyun Kim, Tae Il Kim, Kum-Hee Yun, Young Suk Park, Jeong Eun Kim, Kyu Sang Lee, Jung Kyoon Choi, Hyo Song Kim
Cancer Res Treat. 2022;54(4):1240-1255.   Published online January 17, 2022    DOI: https://doi.org/10.4143/crt.2021.1194
                              Supplementary         Cited By 2
Factors Influencing Imatinib-Induced Hepatotoxicity
Ji Min Han, Jeong Yee, Yoon Sook Cho, Hye Sun Gwak
Cancer Res Treat. 2020;52(1):181-188.   Published online June 26, 2019    DOI: https://doi.org/10.4143/crt.2019.131
                                 Cited By 7
Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
Cancer Res Treat. 2016;48(4):1155-1166.   Published online June 24, 2016    DOI: https://doi.org/10.4143/crt.2016.187
                                 Cited By 89
A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets
Rachna Arora, Manju Sharma, Tausif Monif, Sunil Iyer
Cancer Res Treat. 2016;48(3):1120-1129.   Published online February 12, 2016    DOI: https://doi.org/10.4143/crt.2015.436
                                 Cited By 7
Effect on Cell Cycle Progression by N-Myc Knockdown in SK-N-BE(2) Neuroblastoma Cell Line and Cytotoxicity with STI-571 Compound
Un-Young Yu, Je-Eun Cha, Sun-Young Ju, Kyung-Ah Cho, Eun-Sun Yoo, Kyung-Ha Ryu, So-Youn Woo
Cancer Res Treat. 2008;40(1):27-32.   Published online March 31, 2008    DOI: https://doi.org/10.4143/crt.2008.40.1.27
                                 Cited By 6
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Impact factor
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI